Thromboelastographic monitoring of the effect of unfractionated heparin in healthy dogs

J Vet Emerg Crit Care (San Antonio). 2017 Jan;27(1):71-81. doi: 10.1111/vec.12526. Epub 2016 Oct 12.

Abstract

Objective: To characterize the correlation between thromboelastography (TEG) variables using strong activators and anti-Xa (AXa) activity in healthy dogs administered subcutaneous unfractionated heparin (UFH).

Design: Prospective experimental study.

Setting: University research facility.

Animals: Eight adult random-source male dogs.

Intervention: Dogs were randomized to receive subcutaneous UFH at 200, 250, or 300 IU/kg every 8 hours for a total of 10 injections. Blood samples were collected at time 0 (preheparin) and 3, 6, and 8 hours after the 1st (Day 1) and 10th (Day 4) UFH injection. After the 8-hour blood sample was obtained on day 4, a 100 IU/kg IV bolus of UFH was administered and an additional blood sample was collected 1 hour later (hour 9). AXa activity, activated partial thromboplastin time (aPTT), and TEG (with up to 5 activators) were performed at each time point. Modes of activation for TEG included recalcified (Ca), Ca with heparinase (CaH), CaH and tissue factor 1:3600 (CTF3600H), Ca with tissue factor 1:100 (CTF100), and RapidTEG. Spearman rank correlations were calculated for each of the aforementioned parameters and the AXa activity. P-values were corrected for multiple comparisons with a Bonferroni correction.

Measurements and main results: Significant correlations were found between AXa activity and the TEG R values generated with CTF100 (R = 0.83, P ≤ 0.0001) and RapidTEG (R = 0.90, P < 0.0001), as well as both forms of aPTT measurement (R = 0.86 and 0.84, P < 0.0001).

Conclusions: This study demonstrates that TEG variables derived using robust activation correlate with AXa activity as well as aPTT and have the potential to be used for monitoring UFH therapy in healthy dogs. Future studies are warranted to evaluate its diagnostic utility in critically ill animals.

Keywords: RapidTEG; anti-Xa; anticoagulation monitoring; canine; thrombosis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Anticoagulants / administration & dosage
  • Anticoagulants / pharmacology*
  • Blood Coagulation / drug effects*
  • Dogs
  • Female
  • Heparin / administration & dosage
  • Heparin / pharmacology*
  • Injections, Subcutaneous / veterinary
  • Male
  • Partial Thromboplastin Time / veterinary
  • Prospective Studies
  • Reference Values
  • Thrombelastography / veterinary

Substances

  • Anticoagulants
  • Heparin